GlassScriptPhysician profile
Ella Uvadyeva
NPI 1003110180
$5,221.73
in general payments reported to CMS, 2019-2025
30 companies · $51.86 in 2025
The $51.86 reported for 2025 was less than what a typical Obstetrics & Gynecology provider received nationally (typical 2025 total: $158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,936 · 2020: $486 · 2021: $490 · 2022: $1,064 · 2023: $713 · 2024: $480 · 2025: $51.86.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $972 · Education: $272.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $972.19 |
| Education | $272.48 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $909.87 | 2019-2024 | Prolia, Evenity |
| Gen-Probe, INC. | $557.78 | 2019 | |
| Abbvie INC. | $534.12 | 2019-2022 | |
| Astellas Pharma US INC | $511.51 | 2019-2025 | Veozah, Myrbetriq |
| Celularity INC. | $300.00 | 2019 | |
| Sumitomo Pharma America, INC. | $237.98 | 2023-2024 | Myfembree |
| Pfizer INC. | $230.16 | 2019-2024 | |
| Coopersurgical, INC. | $226.31 | 2019-2023 | Paragard T 380a |
| Exeltis, USA INC. | $171.30 | 2019-2023 | Slynd |
| Roche Diagnostics Corporation | $169.53 | 2019 | |
| Hologic Sales and Service, LLC | $111.34 | 2023-2025 | Myosure Tissue Removal Device, Omni Hysteroscope, Novasure |
| Myovant Sciences INC. | $109.10 | 2021-2022 | |
| Agile Therapeutics, INC. | $107.47 | 2021-2023 | Twirla |
| Merck Sharp & Dohme LLC | $107.21 | 2019-2024 | Gardasil 9, Gardasil |
| Aspira Women'S Health INC | $105.84 | 2021-2022 |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Scynexis, INC. | $87.23 | 2022 | |
| Daiichi Sankyo INC. | $82.88 | 2020-2022 | |
| Lupin INC. | $82.71 | 2019-2020 | |
| Evofem Biosciences, INC. | $75.95 | 2021-2024 | Phexxi |
| Amag Pharmaceuticals, INC. | $74.61 | 2019 | |
| Organon LLC | $74.33 | 2022-2023 | Nexplanon |
| Therapeuticsmd, INC. | $70.40 | 2019-2021 | |
| Allergan, INC. | $66.19 | 2019-2020 | |
| Mayne Pharma Commercial LLC | $60.79 | 2021-2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $36.63 | 2020 | |
| Medicem INC. | $34.24 | 2022 | |
| Mission Pharmacal Company | $25.95 | 2019-2020 | |
| Avion Pharmaceuticals | $25.69 | 2019 | |
| Channel Medsystems, INC. | $18.38 | 2022 | |
| Dysis Medical, INC. | $16.23 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ella Uvadyeva listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.